Archive for the ‘Testing’ Category

Study Finds Classical Lyme Testing Does Not Aid in Diagnosis of Persistent Symptoms

https://www.mdpi.com/2075-1729/13/5/1134

Classical Borrelia Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study

*Author to whom correspondence should be addressed.
Life 202313(5), 1134; https://doi.org/10.3390/life13051134
Received: 27 March 2023 / Revised: 2 May 2023 / Accepted: 3 May 2023 / Published: 6 May 2023
(This article belongs to the Special Issue Lyme Disease-An Incompletely Solved Puzzle)

Abstract

Objective: The diagnosis of Lyme borreliosis is based on two-tier testing using an ELISA and Western blot. About 5–10% of patients report persistent symptoms of unknown etiology after treatment, resulting in substantial difficulties in further diagnostic workup. This paper presents a study aimed at determining whether serology can differentiate between patients with persistent symptoms attributed to Lyme and other patients with Lyme borreliosis.
Methods: A retrospective cohort study included 162 samples from four subgroups: patients with persistent symptoms of Lyme (PSL), early Lyme borreliosis with erythema migrans (EM), patients tested in a general practitioner setting (GP), and healthy controls (HC). ELISA, Western blots, and multiplex assays from different manufacturers were used to determine inter-test variations in PSL and to compare reactivity against Borrelia-specific antigens among the groups.
Results: In comparing the IgG and IgM reactivity by Western blot, IgG was more often positive in the PSL group than in the GP group. The individual antigen reactivity was similar between the PSL and EM or GP groups. Inter-test agreement among the manufacturers was variable, and agreement was higher for IgG testing compared to IgM.
Conclusions: Serological testing is unable to define the subgroup of patients with persistent symptoms attributed to Lyme borreliosis. Additionally, the current two-tier testing protocol shows a large variance among different manufacturers in these patients.
_________________
**Comment**
Another study showing the obvious: Lyme testing sucks all around.
A few points:
  • If I’ve said it once, I’ve said it 1,000 times: all percentages regarding Lyme/MSIDS are always, repeat always, horrifically low.  The numbers of people suffering from persistent symptoms is far, far greater than 5-10%.  The reasons are two-fold: 1) percentages touted only count those diagnosed and treated early  2) people are typically not diagnosed early due to the faulty testing  Everything regarding Lyme/MSIDS is driven by a vortex of circular reasoning without end and nothing ever changes.
  • Now, yet another study proves testing sucks.
  • The question is, and has always been, when is something going to be done about this other than the creation of a supposed magic-bullet and lucrative Lyme “vaccine” that historically has maimed people?

For more:

The form of testing used to determine Lyme infection has been a source of heated debate from the beginning:  https://madisonarealymesupportgroup.com/2018/04/03/cdc-deliberately-avoids-direct-detection-testing-methods-for-ld/  Excerpt:

It would appear that there has been a deliberate avoidance of direct detection methods and it is believed that these efforts are to insure that the current thirty year dogma remain intact.

We have a dire need to develop rapid detection methods for a serious growing health threat which has the ability to disable its victim as described in the attached letter addressed to the previous Director of the CDC. (Please see attachment in link)

I would like to point out that employees of the U.S. Centers for Disease Control hold patents on metabolomics (Lyme tests).

CDC Employee Patent: https://www.google.com/patents/EP2805168A1?cl=en

For nearly four decades now the only FDA approved test for Lyme disease is the indirect two-tiered antibody test. Direct detection methods to identify the causative agent responsible for the disease have been avoided, criticized and shelved.

After publishing the 2013 article ‘A simple method for the detection of live Borrelia spirochetes in human blood using classical microscopy techniques’, professor Laane was invited to give a lecture at the 2014 Norvect conference in Oslo. An English patient saved the pdf, so you can still read it, via the link provided.

I was present at that conference and still remember how nervous he was. The reason was that several medical professors complained to his university. He was threatened with losing his job, if he would speak at the conference.

In fact, he did not literally speak – as you can see in the movie below – but used performing arts to show the slides of the spirochetes. Professor Laane was fired anyway and his laboratory was closed down.

It must be understood that testing has and continues to be used by ‘the powers that be’ to control the narrative.  They can virtually create a ‘pandemic’ anytime they want, and conversely deny a true pandemic.  Regarding Lyme, the narrative has been and continues to be that it is a simple nuisance either causing an immune response or is simply cured with a few weeks of doxycycline monotherapy.  Nothing could be further from the truth and reality and science continue to show this, but is simply ignored.  Go here for the CDC playbook.  Once you understand their MO, everything else makes sense.

Best Lab Test for Lyme, Bartonella, & Babesia

https://www.treatlyme.net/guide/best-lab-test-for-borrelia-bartonella-babesia  Video Here (Approx. 8 Min)

Immunoblot is Best Test for Lyme, Bartonella, and Babesia—Here is Why

By Dr. Marty Ross

This video article on testing has two parts.

  • First, I review the differences between IGenex Immunoblot and Armin or Infectolab Americas Elispot testing for the big three tick-borne infections of Borrelia (Lyme), Babesia and Bartonella.
  • The last section of the video compares IGenex Immunoblot and Galaxy Labs PCR tests for Bartonella.

There is clarifying information below the video. Here you can find more information about the meaning of sensitivity and specificity. I also identify the different strains IGenex detects versus the more limited strains Armin or Infectolab Americas detects. Finally, I explain why I do not use Vibrant Labs or DNA Connexions testing.

Terms and Definitions for Tests

To help understand when to use a test or the meaning of a result physicians consider the test sensitivity and specificity.

  • Sensitivity is the ability of a test to find an illness in all people with the illness.
  • Specificity is the ability of a test to correctly identify people without an illness from all people who do not have the illness.

IGenex Immunoblots are Best Because They are Most Sensitive and Specific

IGenex Immunoblot testing is more sensitive for Borrelia, Babesia, and Bartonella testing than Armin and Infectolab Elispot testing because it looks for reactions to more strains of each infection.

  • Borrelia. The test detects antibodies against eight strains including B. afzelii, B. garinii, and B. burgdorferi.
  • Bartonella. The test detects antibodies against the family of Bartonella which includes 15 types thought to infect humans. In addition, it detects specific antibodies against four specific strains named B. henselae, B. vinsonii, B. elizabethae, and B. quintana.
  • Babesia. The test detects antibodies against the family of Babesia which includes B. odecoilei. It also detects specific antibodies against two specific strains named B. microti, and B. duncani.

(See link for article and video)

________________

For more:

Diagnosing Lyme Disease: Dr. Klinghardt

https://www.bitchute.com/video/IcgYf2AZGfyu/  Video Here (Approx. 1 hour 30 min)

Diagnosing Lyme Disease

Interview with Dr. Dietrich Klinghardt

First published April 2022

For more:

Case Report: Lyme Neuroborreliosis Triggers Multiple Strokes

https://danielcameronmd.com/lyme-neuroborreliosis-triggers-multiple-strokes/

CASE REPORT: LYME NEUROBORRELIOSIS TRIGGERS MULTIPLE STROKES

Lyme disease can trigger neurological complications. But neurovascular manifestations are far less common. In this case report, the authors describe a 58-year-old man who suffered multiple strokes due to Lyme neuroborreliosis.

In their article, “A case report of unilateral cerebral vasculitis in adults: keep in mind Lyme neuroborreliosis,” Riescher and colleagues examine the case of a 58-year-old man “with recurrent strokes in the same vascular territory without CSF pleocytosis, reflecting an unusual first manifestation of [Lyme neuroborreliosis].”¹

The authors point out that cerebral vasculitis is reported in only 0.3–1% of all Lyme neuroborreliosis cases, and unilateral or focal vasculitis have only rarely been described, almost exclusively in children.

In this case report, the patient, who had no medical history or cardiovascular risk factors, was admitted to the hospital with sudden right brachiofacial weakness. According to the authors, “He recovered partially, but facial palsy persisted.”

He was referred to the stroke unit but a neurological and general examination was normal.

“Cervical and intracranial CT angiography did not show any abnormalities such as stenosis, occlusion, or dilatation,” the authors wrote.

The man was diagnosed with cryptogenic stroke and prescribed aspirin (160  mg), atorvastatin (80 mg), and perindopril at 2 mg daily.

Two months later, the man exhibited sudden aphasia.

“Burgdorferi-induced cerebral vasculitis is thought to be a very rare manifestation of [Lyme neuroborreliosis]. But it must nonetheless be considered in the differential diagnosis of unexplained recurrent and/or multiple strokes.”

“MRI revealed a new and recent ischemic lesion in the left MCA territory visible on DWI, and another older lesion in the anterior cerebral artery (ACA) territory,” the authors wrote.

The patient was prescribed an oral anticoagulant and a cardiac monitor was inserted.

Over the next several months, the patient developed new symptoms including paresthesia (tingling sensation) in the right hand and foot, headaches, extreme weakness and lack of energy, psychomotor retardation, and unsteadiness.

Thirteen months after his first symptom appeared, he developed paresis (muscle weakness) in his right leg.

“A brain MRI showed a new recent ischemic lesion in the left cingulate cortex on DWI in the left ACA territory as well as other new lesions in the left MCA territory (in the frontal lobe),” the authors wrote.

Additional neurological testing was normal. However, Lyme disease testing was “highly positive” on ELISA and confirmed by Western blot.

The man was successfully treated with a one-month course of doxycycline.

“The patient experienced no further stroke after four weeks of doxycycline treatment.”

“In the following weeks, the patient reported dramatic improvement, with disappearance of his asthenia, dizziness, and right arm paresthesia,” the authors wrote.

The patient later reported that he had a tick bite 2 years prior to his first stroke, along with an erythema migrans rash but he never developed arthritis or pain.

Authors Conclude:

  • “Our patient stood out because he had recurrent ischemic strokes for more than one year (at least four episodes), without other associated symptoms, involving the ICA territory only, and without CSF pleocytosis, which is thought to be highly suggestive of LNB.”
  • “Burgdorferi-induced cerebral vasculitis is thought to be a very rare manifestation of [Lyme neuroborreliosis]. But it must nonetheless be considered in the differential diagnosis of unexplained recurrent and/or multiple strokes.”
  • “This case report reminds clinicians that it can occur without a history of a clear tick bite or erythema migrans, and cranial or peripheral neuritis and that the CSF examination can be normal.”
References:
  1. Riescher, S., Dos Santos, A., Lecomte, R. et al. A case report of unilateral cerebral vasculitis in adults: keep in mind Lyme neuroborreliosis. BMC Infect Dis 23, 283 (2023). https://doi.org/10.1186/s12879-023-08259-z

__________________

**Comment**

I’ve stated this before but it’s worth repeating: many Lyme/MSIDS patients improve by taking blood thinners or anti-coagulants like heparin, systemic enzymes, and things like serrapeptase, nattokinase & lumbrokinase which have a blood thinning effect.  Considering that many pathogens form biofilm, thinning and thereby cleaning the blood seems a logical step in helping treatment be more effective.

Is Your Home Making You Sick? How To Check For Mold

https://www.lymedisease.org/how-to-check-for-mold-iseai/

Is your home making you sick? Here’s how to check for mold.

The International Society for Environmentally Acquired Illness (ISEAI) Indoor Environmental Professional (IEP) Committee has released a Mold Testing Guide to educate patients with diagnosed or probable environmentally acquired illness.

It includes five common test types, do-it-yourself and professional approaches, and how to get help to assess and improve your home’s indoor air quality.

Environmentally acquired illness (EAI) refers to chronic health problems caused by exposure to unhealthy indoor air, mold and other biotoxins, Lyme disease and other persistent infections, and toxicants found in the environment.

Understanding Mold Exposure and Your Health

Awareness about mold’s effect on human health, and indoor air quality in general, has been increasing over the past few years. Several types of illnesses may be caused by exposure to mold and other toxins in damp buildings and they can often become complex and chronic, with symptoms similar to Lyme disease and its co-infections.

Mold exposure from damp buildings may lead to chronic inflammation and can be a primary exposure factor in the clinical presentation of individuals suffering from a variety of chronic health issues due to environmental exposures.

A medically-sound indoor environmental professional is often needed to help sensitive patients, but worth it. Some patients with Lyme disease may find it more difficult to heal in an unhealthy building that is affected by mold.

Unfortunately, there are currently no US Federal or State regulated levels set for indoor mold exposures and interpretation of environmental sample data can be very subjective and vary from one professional to another.

The Mold Testing Guide can help educate patients and physicians about this important topic.

A Healthy Indoor Environment

ISEAI feels that a healthy indoor environment is free of water damage, fungal and microbial growth, and byproducts of that growth (mycotoxins, mVOCs, fragments).

That said, there is no such thing as a truly “mold free” home, since fungal spores exist in the natural outdoor environment. A goal is to maintain an indoor environment that resembles the natural outdoor environment as much as possible, without undue elevations.

In addition to a thorough visual assessment by a professional, the results of environmental testing such as mold testing may allow sensitive patients to better understand their exposure levels, and take appropriate action if needed.

About ISEAI

ISEAI is a 501(c)(3) non-profit organization co-founded by 350+ clinician members to raise awareness about the environmental causes of complex chronic illness and to advance the care of patients through clinical practice, education and research. Their vision is a world where a wide range of clinicians have the knowledge and skills to diagnose and treat the root causes of debilitating complex chronic and inflammatory illnesses.

About the IEP Committee

ISEAI’s IEP Committee is a group of highly credentialed and experienced indoor environmental professionals who have specialized experience with medically-sensitive patients. The Committee reports to the ISEAI Board of Directors and provides education to clinicians and the public on topics of mold, indoor air quality and contaminants.

Additional Resources

ISEAI’s Resources Page includes other IEP Committee documents such as the Mold Remediation Factsheet and a directory of medically-sound IEPs and clinicians.

Also read: Finding the Right Indoor Environmental Professional to Assess Your Home.

SOURCE: The International Society for Environmentally Acquired Illness

For more: